0

Levodopa Related Compound B

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP7636262
CAS7636-26-2
Structure
Molecular Weight211.21
DescriptionUnited States Pharmacopeia (USP) Reference Standard
Formneat
Size50MG
1

Dual-target-directed Drugs That Block Monoamine Oxidase B and Adenosine A(2A) Receptors for Parkinson's Disease

Jacobus P Petzer, Neal Castagnoli Jr, Michael A Schwarzschild, Jiang-Fan Chen, Cornelis J Van der Schyf

Neurotherapeutics. 2009 Jan;6(1):141-51.

PMID: 19110205

1

Non-motor Symptoms in Parkinson's Disease Patients With Parkin Mutations: More Depression and Less Executive Dysfunction

Jie Song, Bo Shen, Yu-Jie Yang, Feng-Tao Liu, Jue Zhao, Yi-Lin Tang, Chen Chen, Zheng-Tong Ding, Yu An, Jian-Jun Wu, Yi-Min Sun, Jian Wang

J Mol Neurosci. 2020 Feb;70(2):246-253.

PMID: 31927768

1

Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on levodopa/carbidopa/entacapone for Treatment of Levodopa-Associated Motor Complications

Thomas Müller

Clin Neuropharmacol. May-Jun 2013;36(3):84-91.

PMID: 23673910

1

Pharmacokinetic Drug Evaluation of Safinamide Mesylate for the Treatment of Mid-To-Late Stage Parkinson's Disease

Thomas Müller

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693-699.

PMID: 28537214

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode